TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15310997

Group type: EXPERIMENTAL
Intervention: Dutasteride (5 mg per day for 6 to 10 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 11764017

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9663367

Group type: EXPERIMENTAL
Intervention: Venlafaxine (200 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7875435

Group type: EXPERIMENTAL
Intervention: Enprostil (35 micrograms bid)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg bid)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison of Ranitidine and Enprostil
Number of subjects: 12
Study: 2975684

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg once daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31481243

Group type: EXPERIMENTAL
Intervention: ACC/AHA criteria for hypertension diagnosis
Number of subjects: 370
Study: 29097299

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100mg daily)
Number of subjects: 1400
Study: 27288347

Group type: EXPERIMENTAL
Intervention: LdP intervention
Number of subjects: 989

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 989
Study: 24074852

Group type: EXPERIMENTAL
Intervention: Adjective Rating Scale for Withdrawal (ARSW)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Change from post-treatment through follow-up
Number of subjects: 515
Study: 23044413

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (33 °C) for one hour (n=5)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (33 °C) for twenty-four hours (n=9)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no hypothermia)
Number of subjects: 14
Study: 21072246

Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg orally twice daily plus zanamivir 10 mg by inhalation twice daily (OZ)
Number of subjects: 541

Group type: COMPARATOR
Intervention: Oseltamivir plus inhaled placebo (O)
Number of subjects: 541

Group type: COMPARATOR
Intervention: Zanamivir plus oral placebo (Z)
Number of subjects: 541
Study: 18990048

Group type: EXPERIMENTAL
Intervention: Integrated acupuncture, tuina, and rehabilitation (physiotherapy, occupational therapy, and hydrotherapy) for 12 weeks (Group I)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Rehabilitation (physiotherapy, occupational therapy, and hydrotherapy) for 12 weeks followed by acupuncture and tuina for 12 weeks (Group II)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (both groups)
Number of subjects: 116
Study: 17020559

Group type: EXPERIMENTAL
Intervention: Postconditioning (PCI with postconditioning)
Number of subjects: 94

Group type: COMPARATOR
Intervention: IR group (PCI without postconditioning)
Number of subjects: 94
Study: 12837190

Group type: EXPERIMENTAL
Intervention: ACD-CPR (cardio pump)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 92
Study: 10739150

Group type: EXPERIMENTAL
Intervention: Transposition of the IDN into the intermuscular space
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard resection operation
Number of subjects: 44
Study: 8652909

Group type: EXPERIMENTAL
Intervention: Ondansetron combined with corticosteroids for acute cisplatin-induced emesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 1308663

Group type: EXPERIMENTAL
Intervention: Fluconazole (100 mg/d)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Ketoconazole (200 mg/d)
Number of subjects: 169
Study: 3931924

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis (Enterogermina, Midy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 30
Study: 31310160

Group type: EXPERIMENTAL
Intervention: Long-term methimazole therapy (60-120 months)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Conventional methimazole therapy (18-24 months)
Number of subjects: 302
Study: 30156175

Group type: EXPERIMENTAL
Intervention: Military-approved uniforms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospital-provided scrubs
Number of subjects: 0
Study: 26489045

Group type: EXPERIMENTAL
Intervention: rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF)
Number of subjects: 786

Group type: COMPARATOR
Intervention: efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF)
Number of subjects: 786
Study: 25290556

Group type: EXPERIMENTAL
Intervention: augmented smartphone application
Number of subjects: 28

Group type: COMPARATOR
Intervention: standard smartphone application
Number of subjects: 28
Study: 22924638

Group type: EXPERIMENTAL
Intervention: FFR-guided PCI plus the best available medical therapy
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Best available medical therapy alone
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Registry patients (best available medical therapy)
Number of subjects: 1220
Study: 19330342

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol/cyproterone acetate (EE/CA)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: EE/CA-metformin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: metformin alone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: EE/CA-spironolactone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: EE/CA
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 48
Study: 17355402

Group type: EXPERIMENTAL
Intervention: Nurse home visiting programs for pregnant women and parents of young children
Number of subjects: 0
Study: 15737251

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 45
Study: 12206949

Group type: EXPERIMENTAL
Intervention: 1.5-4 months post-ACL reconstruction
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 6-7 months post-ACL reconstruction
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 12-15 months post-ACL reconstruction
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no history of lower extremity pathology/injury)
Number of subjects: 96
Study: 9689432

Group type: EXPERIMENTAL
Intervention: Nutrient-mixture (Aminoleban EN) 100 g/day for 2 to 6 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no nutrient-mixture)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nutrient-mixture (Aminoleban EN)
Number of subjects: 18
Study: 7806469

Group type: EXPERIMENTAL
Intervention: Cold Water immersion (0 degree C) of the right hand
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cold Water immersion (0 degree C) of the left hand
Number of subjects: 15

Group type: COMPARATOR
Intervention: Warm Water immersion (control)
Number of subjects: 15
Study: 2777728

Group type: EXPERIMENTAL
Intervention: Intravenous gentamicin and 12 g/day piperacillin
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Intravenous gentamicin and 8 g/day piperacillin
Number of subjects: 127

Group type: COMPARATOR
Intervention: Intravenous gentamicin and piperacillin (both doses)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Further antibiotics added to unresponsive patients
Number of subjects: 127
Study: 29762196

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Continuous Aerobic (CA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Delayed Control
Number of subjects: 32
Study: 28814835

Group type: EXPERIMENTAL
Intervention: Generic formulation of atorvastatin (Atorva®) 20 mg once daily
Number of subjects: 376

Group type: COMPARATOR
Intervention: Reference formulation of atorvastatin (Lipitor®) 20 mg once daily
Number of subjects: 376
Study: 25712802

Group type: EXPERIMENTAL
Intervention: 1-month BCI-supported MI training (BCI group, n=14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 1-month MI training without BCI support (control group; n=14)
Number of subjects: 28
Study: 23155122

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 47
Study: 20185409

Group type: EXPERIMENTAL
Intervention: 40-microg Engerix-B
Number of subjects: 87

Group type: COMPARATOR
Intervention: 80-microg Engerix-B
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Seroconversion (both groups)
Number of subjects: 87
Study: 18823024

Group type: EXPERIMENTAL
Intervention: Uracil/tegafur (UFT) and gemcitabine (GEM) together (GU)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gemcitabine (G) alone
Number of subjects: 100
Study: 16215367

Group type: COMPARATOR
Intervention: Control groups from recent randomized controlled trials on severe sepsis
Number of subjects: 70000
Study: 12820466

Group type: EXPERIMENTAL
Intervention: Intraarterial continuous infusion of cisplatin (CDDP), 24 mg/m2/day
Number of subjects: 123

Group type: COMPARATOR
Intervention: Bolus of cisplatin (CDDP), 24 mg/m2/day
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Both arms received i.v. escalating doses of fluorouracil
Number of subjects: 123
Study: 11113295

Group type: EXPERIMENTAL
Intervention: Placebo and hidden naloxone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hidden naloxone only
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Placebo and hidden saline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hidden saline only
Number of subjects: 60
Study: 8839635

Group type: EXPERIMENTAL
Intervention: New delayed-release formulation of UDCA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional pH-dependent sequential release formulation of UDCA
Number of subjects: 0
Study: 1948791

Group type: EXPERIMENTAL
Intervention: Inhaled PGE2 (100 micrograms)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 6421010

Group type: EXPERIMENTAL
Intervention: 1 mg buccal nitroglycerin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2.5 mg buccal nitroglycerin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5.0 mg buccal nitroglycerin
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.8 mg sublingual nitroglycerin
Number of subjects: 60
Study: 31069557

Group type: EXPERIMENTAL
Intervention: Robot-assisted ventral mesh rectopexy (RVMR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Laparoscopic ventral mesh rectopexy (LVMR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: RVMR compared to LVMR
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both RVMR and LVMR
Number of subjects: 30
Study: 28196503

Group type: EXPERIMENTAL
Intervention: G-MISS questionnaire
Number of subjects: 2055

Group type: COMPARATOR
Intervention: Medical or surgical specialties
Number of subjects: 2055

Group type: COMPARATOR
Intervention: Consultation shorter than 5 minutes
Number of subjects: 2055
Study: 27040324

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic-valve replacement (TAVR)
Number of subjects: 2032

Group type: COMPARATOR
Intervention: Surgical aortic-valve replacement
Number of subjects: 2032

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic-valve replacement (TAVR) in transfemoral-access cohort
Number of subjects: 2032

Group type: COMPARATOR
Intervention: Surgical aortic-valve replacement in transfemoral-access cohort
Number of subjects: 2032
Study: 25095775

Group type: EXPERIMENTAL
Intervention: Vestibulopathy with visual vertigo (VV)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28
Study: 22822451

Group type: EXPERIMENTAL
Intervention: NuFit active blend (2.25 g leucine and 30 mg pyridoxine)
Number of subjects: 20
Study: 19535190

Group type: EXPERIMENTAL
Intervention: Nicorandil, 15 mg/d
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control (no nicorandil)
Number of subjects: 129
Study: 16636341

Group type: EXPERIMENTAL
Intervention: sorafenib (400 mg twice daily)
Number of subjects: 202

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: entire renal cell carcinoma population
Number of subjects: 202
Study: 14673047

Group type: EXPERIMENTAL
Intervention: Surgery plus chemotherapy (cisplatin 80 mg/m2 x 1 day and fluorouracil 800 mg/m2 x 5 days)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Surgery plus chemotherapy
Number of subjects: 242
Study: 11196553

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study: 8818438

Group type: EXPERIMENTAL
Intervention: Two-legged knee extensor training (n = 7) for 15 min at 65-75% of VO2 max (about 4 kg working muscle)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: One-legged dynamic knee extensor training (n = 7) for 15 min at 35% of VO2 max (about 2 kg working muscle)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 14
Study: 1610576

Group type: EXPERIMENTAL
Intervention: Methohexital anesthesia (0.5 to 1.0 mg/kg) with atropine premedication
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Methohexital anesthesia (0.5 to 1.0 mg/kg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Atropine premedication
Number of subjects: 49
Study: 6148881

Group type: EXPERIMENTAL
Intervention: Nadolol (80 to 320 mg for 6 weeks)
Number of subjects: 8
Study: 31517543

Group type: EXPERIMENTAL
Intervention: Child STEPs treatment program
Number of subjects: 156

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 156
Study: 30845320

Group type: EXPERIMENTAL
Intervention: Vi-Typhoid Conjugate Vaccine (Vi-TCV)
Number of subjects: 28000

Group type: COMPARATOR
Intervention: Meningococcal serogroup A conjugate vaccine (control)
Number of subjects: 28000
Study: 29524194

Group type: EXPERIMENTAL
Intervention: Low-Se diet (−Se group, 0.033 mg/kg Se)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Basal diet (control group, 0.2 mg/kg Se)
Number of subjects: 120
Study: 27965256

Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 42

Group type: COMPARATOR
Intervention: Minimal acupuncture
Number of subjects: 42
Study: 24652419

Group type: EXPERIMENTAL
Intervention: Proximal Femoral Nail (PFN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Reverse Distal Femoral Locking Compression Plate (reverse-DFLCP)
Number of subjects: 40
Study: 22688598

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 19173706

Group type: EXPERIMENTAL
Intervention: 4 SNPs at the 9p21 locus
Number of subjects: 332
Study: 17159195

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg intravenously every 6 months)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Endocrine therapy without zoledronic acid
Number of subjects: 401

Group type: COMPARATOR
Intervention: Anastrozole/goserelin
Number of subjects: 401

Group type: COMPARATOR
Intervention: Tamoxifen/goserelin
Number of subjects: 401
Study: 16371734

Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography +/‐ endoscopic sphincterotomy (ERCP +/‐ ES) within 48 hours
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conservative treatment and selective ERCP +/‐ ES after 48 hours
Number of subjects: 61
Study: 12783774

Group type: EXPERIMENTAL
Intervention: Normal diet (NF) containing 39% energy as fat
Number of subjects: 9

Group type: COMPARATOR
Intervention: Carbohydrate-rich athlete's diet (LF) containing 24% energy as fat
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: During exercise
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fluorescence microscopy
Number of subjects: 9
Study: 10632835

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 11

Group type: COMPARATOR
Intervention: Warfarin vs Aspirin
Number of subjects: 11
Study: 9239866

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring (ABPM)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Casual blood pressure measurement
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure average values for two or 24 hours
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Echocardiogram
Number of subjects: 31
Study: 1295122

Group type: EXPERIMENTAL
Intervention: Nitrendipine (Nidrel 20 mg) administered once daily in the morning
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nitrendipine (Nidrel 20 mg) administered once daily in the evening
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nitrendipine (Nidrel 20 mg) administered once daily (both morning and evening)
Number of subjects: 41
Study: 6203228

Group type: EXPERIMENTAL
Intervention: Levamisole (decaris) as an interferon inducer
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no levamisole)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Levamisole (decaris)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Severe forms of influenza (control group)
Number of subjects: 74
Study: 31790484

Group type: EXPERIMENTAL
Intervention: Add-on training program involving breathing exercises, cold exposure, and meditation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study: 29458218

Group type: EXPERIMENTAL
Intervention: Curcuminoids plus piperine (500 mg/day curcuminoids and 5 mg/day piperine)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 26654200

Group type: EXPERIMENTAL
Intervention: Baseline BP
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Baseline MSNA
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Follow-up BP
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Follow-up MSNA
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Correlation of SBP and DBP at baseline
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Correlation of SBP and DBP at follow-up
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: MSNA tracking correlation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Correlation of MSNA and DBP at baseline
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Correlation of MSNA and DBP at follow-up
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: BMI change at follow-up
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Sympathetic responses to handgrip and mental stressors
Number of subjects: 13
Study: 24121756

Group type: EXPERIMENTAL
Intervention: TMC310911 75 mg bid
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: TMC310911 150 mg bid
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: TMC310911 300 mg bid
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: TMC310911 300 mg qd
Number of subjects: 33
Study: 23145859

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam 500 mg plus avibactam 125 mg every 8 hours for 7-14 days
Number of subjects: 135

Group type: COMPARATOR
Intervention: Imipenem-cilastatin 500 mg every 6 hours for 7-14 days
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Number of subjects: 135

Group type: COMPARATOR
Intervention: Imipenem-cilastatin
Number of subjects: 135
Study: 21030934

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) for secondary prevention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) for primary prevention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emerging data on ASA efficacy and safety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strategies to enhance safety and efficacy of ASA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consideration of ASA prescription
Number of subjects: 0
Study: 18572751

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 10 mg/day
Number of subjects: 0
Study: 16038683

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 536

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536
Study: 12718834

Group type: EXPERIMENTAL
Intervention: Exposure to human wastes (occupational groups)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Consumption of drinking water from New Zealand supplies other than metropolitan mains supplies
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Consumption of drinking water from sources outside New Zealand
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Traveling
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Swimming in pools or fresh water at least once a week
Number of subjects: 519
Study: 10811525

Group type: EXPERIMENTAL
Intervention: CYCLO 3 FORT
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hydroxyethyl rutoside (rutoside)
Number of subjects: 80
Study: 8526578

Group type: EXPERIMENTAL
Intervention: Shouldice repair (stainless steel or polypropylene)
Number of subjects: 1578

Group type: COMPARATOR
Intervention: Bassini's repair
Number of subjects: 1578

Group type: COMPARATOR
Intervention: Cooper's ligament repair
Number of subjects: 1578

Group type: EXPERIMENTAL
Intervention: Shouldice repair (stainless steel)
Number of subjects: 1578

Group type: EXPERIMENTAL
Intervention: Shouldice repair (polypropylene)
Number of subjects: 1578
Study: 2044551

Group type: EXPERIMENTAL
Intervention: Anistreplase (30 U intravenous injection over 2-5 minutes)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Streptokinase (1,500,000 U intravenous infusion over 60 minutes)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Anistreplase
Number of subjects: 116

Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 116
Study: 7025638

Group type: EXPERIMENTAL
Intervention: Dexamethasone (20 mg, 5 mg every 12 hours, intramuscularly)
Number of subjects: 696

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 696
Study: 31208259

Group type: EXPERIMENTAL
Intervention: Educational Digital Storytelling Intervention (EDSI)
Number of subjects: 98

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 98
Study: 29129737

Group type: EXPERIMENTAL
Intervention: CHO-PUFA diet (low-fat high-carbohydrate diet enriched in n-3 PUFA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CHO-PUFA meal
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mediterranean diet enriched in MUFA with virgin olive oil
Number of subjects: 20

Group type: COMPARATOR
Intervention: SFA-rich diet
Number of subjects: 20